Fixed Dose Heparin Study
Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences-General Campus
-
Hamilton, Ontario, Canada, L8N 3Z5
- Hamlton Health Sciences -McMaster Campus
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare Centre
-
Hamilton, Ontario, Canada, L8V 1C3
- Hamilton Health Sciences-Henderson Campus
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- McGill University Health Centre
-
Quebec City, Quebec, Canada
- CHA Pavillon du Saint-Sacrement
-
-
-
-
-
Auckland, New Zealand
- Auckland Hospital
-
Otahuhu, New Zealand
- Middlemore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A diagnosis of acute venous thromboembolism (VTE,DVT and /or PE)
Exclusion Criteria:
- Contraindication to subcutaneous (sc) route of administration (eg:shock (evidence of poor peripheral perfusion), major surgery within 48 hours)
- Active Bleeding process
- Comorbid condition limiting expected survival to less than 3 months
- Current treatment with therapeutic dose of UFH, LMWH, danaparoid sodium, or a direct thrombin inhibitor for more than 48 hours
- Currently on long term warfarin or heparin therapy
- Allergy to heparin or history of heparin induced thrombocytopenia
- Currently pregnant
- Contraindication to contrast media (eg: allergy or creatinine >200 umol/L).
- Currently enrolled or will be enrolled in a competing study
- Geographically inaccessible for follow-up assessment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Death
|
|
Symptomatic Venous Thromboembolism
|
|
Major Bleeding
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
aXa ~6h after sc injection on 3rd day of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Clive Kearon, MB Ph.D, Hamiton Health Sciences
- Principal Investigator: Jim Julian, MMath, McMaster-Dept. of Clinical Epidemiology &Biostatistics
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTMG-2005-FIDO
- #NA3640
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.